Two opposing gene expression patterns within ATRX aberrant neuroblastoma.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 07 06 2023
accepted: 02 07 2023
medline: 7 8 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: epublish

Résumé

Neuroblastoma is the most common extracranial solid tumor in children. A subgroup of high-risk patients is characterized by aberrations in the chromatin remodeller ATRX that is encoded by 35 exons. In contrast to other pediatric cancer where ATRX point mutations are most frequent, multi-exon deletions (MEDs) are the most frequent type of ATRX aberrations in neuroblastoma. 75% of these MEDs are predicted to produce in-frame fusion proteins, suggesting a potential gain-of-function effect compared to nonsense mutations. For neuroblastoma there are only a few patient-derived ATRX aberrant models. Therefore, we created isogenic ATRX aberrant models using CRISPR-Cas9 in several neuroblastoma cell lines and one tumoroid and performed total RNA-sequencing on these and the patient-derived models. Gene set enrichment analysis (GSEA) showed decreased expression of genes related to both ribosome biogenesis and several metabolic processes in our isogenic ATRX exon 2-10 MED model systems, the patient-derived MED models and in tumor data containing two patients with an ATRX exon 2-10 MED. In sharp contrast, these same processes showed an increased expression in our isogenic ATRX knock-out and exon 2-13 MED models. Our validations confirmed a role of ATRX in the regulation of ribosome homeostasis. The two distinct molecular expression patterns within ATRX aberrant neuroblastomas that we identified imply that there might be a need for distinct treatment regimens.

Identifiants

pubmed: 37540673
doi: 10.1371/journal.pone.0289084
pii: PONE-D-23-11824
pmc: PMC10403137
doi:

Substances chimiques

X-linked Nuclear Protein EC 3.6.4.12
Chromatin 0
ATRX protein, human EC 3.6.4.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0289084

Informations de copyright

Copyright: © 2023 van Gerven et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Références

Nat Commun. 2020 Feb 14;11(1):913
pubmed: 32060267
J Cell Biol. 2008 Jan 28;180(2):315-24
pubmed: 18227278
Cell. 2010 Oct 29;143(3):367-78
pubmed: 21029860
Eur J Cancer. 2022 Nov;175:311-325
pubmed: 36182817
Nat Genet. 2015 Dec;47(12):1411-4
pubmed: 26523776
Nucleic Acids Res. 2019 May 7;47(8):e47
pubmed: 30783653
Genes (Basel). 2019 Dec 10;10(12):
pubmed: 31835618
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Nat Protoc. 2019 Mar;14(3):703-721
pubmed: 30804569
EMBO J. 2001 Mar 15;20(6):1383-93
pubmed: 11250904
J Neurooncol. 2014 Aug;119(1):17-26
pubmed: 24792489
Nat Cell Biol. 2005 Mar;7(3):311-8
pubmed: 15723054
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
PLoS One. 2018 Sep 18;13(9):e0204159
pubmed: 30226859
PLoS One. 2014 Jul 17;9(7):e101717
pubmed: 25032825
Cancer Cell. 2019 Nov 11;36(5):512-527.e9
pubmed: 31631027
PLoS Genet. 2021 Nov 15;17(11):e1009909
pubmed: 34780483
Nat Genet. 2021 May;53(5):683-693
pubmed: 33767450
Cell Death Differ. 2022 May;29(5):972-982
pubmed: 35444234
Genome Biol. 2014;15(12):550
pubmed: 25516281
Trends Cancer. 2020 Mar;6(3):247-260
pubmed: 32101727
Oncotarget. 2015 Jun 30;6(18):16543-58
pubmed: 26001292
Eur J Cancer. 2014 Feb;50(3):628-37
pubmed: 24321263
EMBO Rep. 2017 Jun;18(6):914-928
pubmed: 28487353
Aging (Albany NY). 2019 Apr 26;11(8):2512-2540
pubmed: 31026227
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13983-8
pubmed: 10570185
Cancer Sci. 2022 Jun;113(6):2167-2178
pubmed: 35384159
Front Cell Dev Biol. 2020 Feb 11;8:65
pubmed: 32117990
PLoS One. 2014 Mar 20;9(3):e92915
pubmed: 24651726
Semin Cell Dev Biol. 2023 Feb 28;136:13-26
pubmed: 35440410
Nat Commun. 2021 Jun 23;12(1):3887
pubmed: 34162889
Chembiochem. 2016 May 17;17(10):928-35
pubmed: 26991472
Nucleic Acids Res. 2018 Jul 2;46(W1):W242-W245
pubmed: 29762716
J Biol Chem. 2001 Aug 24;276(34):32198-203
pubmed: 11395519
IEEE Trans Vis Comput Graph. 2012 Feb;18(2):321-31
pubmed: 21383412
Nat Cell Biol. 2022 Feb;24(2):135-147
pubmed: 35165420
Nucleic Acids Res. 2015 Jul 27;43(13):6270-84
pubmed: 26038315
Gene. 2004 Feb 4;326:23-34
pubmed: 14729260
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14075-80
pubmed: 20651253
Genes Dev. 1999 Sep 15;13(18):2388-99
pubmed: 10500096
Springerplus. 2014 May 02;3:222
pubmed: 24834375
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34479993
Science. 2018 Dec 7;362(6419):1165-1170
pubmed: 30523111
Epigenetics. 2016 Jun 2;11(6):398-414
pubmed: 27029610
Front Genet. 2018 Nov 15;9:533
pubmed: 30498507
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
EMBO J. 2019 Oct 1;38(19):e96659
pubmed: 31454099
Cell Rep. 2017 Jun 20;19(12):2544-2556
pubmed: 28636942
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1531-6
pubmed: 21205896
EBioMedicine. 2020 Sep;59:102971
pubmed: 32846370

Auteurs

Michael R van Gerven (MR)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Linda Schild (L)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Jennemiek van Arkel (J)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Bianca Koopmans (B)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Luuk A Broeils (LA)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Loes A M Meijs (LAM)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Romy van Oosterhout (R)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Max M van Noesel (MM)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.
Department of Cancer and Imaging, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.

Jan Koster (J)

Department of Oncogenomics, University Medical Center Amsterdam, Amsterdam, North-Holland, The Netherlands.

Sander R van Hooff (SR)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Jan J Molenaar (JJ)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.
Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Utrecht, The Netherlands.

Marlinde L van den Boogaard (ML)

Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH